On the basis of our previous results indicating GIPR activation being antiemetic in lean rats against the preclinical GLP-1R agonist GLP-140 (27), we extended our investigation and tested the ability of GIP-085 to counteract the malaise induced by GLP-1R activation by measuring food intake, body weight, and kaolin consumption in obese rats following a single injection of the preclinical GLP-1R agonist GLP-140 (27). The gene discussed is GIPR; the disease is malaise.